Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus percutaneous alcohol injection changes serious adverse events (number of participants) compared with percutaneous alcohol injection (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes mortality at maximal compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Cancer‐related mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
Percutaneous alcohol injection may leads to higher cancer‐related mortality at maximal compared with radiofrequency ablation (low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of events) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Duration of sensory block (we included all studies describing duration of sensory block regardless of how it was described) · participants undergoing surgery with peripheral nerve block
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · participants undergoing surgery with peripheral nerve block
3 findings from 1 review
no estimate extracted
3 studies · 172 participants
Low
no estimate extracted
3 studies · 162 participants
Low
no estimate extracted
5 studies · 257 participants
Low
Incidence of serious adverse events (we used the NIH definition of adverse events. A serious event includes death, a life‐threatening event that requires hospitalization or prolonged hospitalization, disability or congenital anomaly) · participants undergoing surgery with peripheral nerve block
1 finding from 1 review
Postoperative pain intensity in the immediate postobturation period (up to 72 hours), continuous (VAS) · participants undergoing surgery with peripheral nerve block
3 findings from 1 review
no estimate extracted
5 studies · 257 participants
Very low
no estimate extracted
9 studies · 469 participants
Low
no estimate extracted
3 studies · 296 participants
Low
Duration of sensory block (we included all studies describing duration of sensory block regardless of how it was described) · participants undergoing surgery with peripheral nerve block
1 finding from 1 review
Incidence of serious adverse events (we used the NIH definition of adverse events. A serious event includes death, a life‐threatening event that requires hospitalization or prolonged hospitalization, disability or congenital anomaly) · participants undergoing surgery with peripheral nerve block
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Surgical site infection · S aureus carriers undergoing cardiac surgery
Mupirocin showed no clear difference in SSI compared with placebo (low certainty).
1 finding from 1 review
S aureus SSI · S aureus carriers undergoing cardiac surgery
Mupirocin showed no clear difference in S aureus SSI compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · S aureus carriers undergoing cardiac surgery
Mupirocin showed no clear difference in mortality compared with placebo (low certainty).
1 finding from 1 review
Adverse events · S aureus carriers undergoing cardiac surgery
1 finding from 1 review
Surgical site infection · S aureus carriers undergoing cardiac surgery
It is very uncertain whether anerdian changes SSI compared with no treatment (very low certainty).
1 finding from 1 review
Adverse events · S aureus carriers undergoing cardiac surgery
1 finding from 1 review
Scarring · surgical wounds resulting from a range of surgical procedures with some risk of contamination healing by primary intention
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found